Table 4. Comparison of the clinical presentations of TFE3-positive and TFE3-negative EHEs.
| (%) | TFE3 (+) EHE | TFE3 (−) EHE | P-value |
|---|---|---|---|
| Case number | 5 | 13 | |
| Age at diagnosis (year) | 41.20 ± 5.23 | 53.23 ± 4.30 | 0.1383 |
| Sex (Male:Female) | 2:3 | 6:7 | 1.0000 |
| Follow-up period (month) | 79.00 ± 20.44 | 77.77 ± 37.66 | 0.9743 |
| Overall survival | 5/5 (100.0) | 11/13 (84.6) | 0.3598a |
| Tumor size (cm) | 8.24 ± 3.14 | 3.44 ± 0.80 | 0.0550 |
| Multiplicity | 0/5 (0.0) | 8/13 (61.5) | 0.0359 |
| Local Recurrence b | 0/5 (0.0) | 2/13 (15.4) | 1.0000 |
| Distant Metastasis | 2/5 (40.0) | 6/13 (46.2) | 1.0000 |
a
A statistical difference of overall survival between patients with TFE3-positive and TFE3-negative EHEs by the Kaplan-Meier analysis
b
Tumor recurrence in EHE patients was observed over a follow-up period of two years.